-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2831 Title: Risk Factors and Natural History of Vincristine Induced Neuropathy on UKALL 2011: A Randomised Controlled Trial of the Effect of Omitting Vincristine Pulses

Program: Oral and Poster Abstracts
Session: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Translational Research, Diseases, Lymphoid Malignancies, Adverse Events
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Lucy Alderson1*, Lucy Waller1*, Mario Cortina Borja2*, Amy A Kirkwood3*, Vickaynne Carruthers4*, David Jamieson5*, Pam Kearns, MBChB, PhD, FRCPC6*, Amrana Qureshi7*, Susan Baird8*, Jayashree Motwani9*, Rachael Hough, MD10*, John Moppett11*, Ajay Vora, MD12, Gareth Veal, PhD4* and Sujith Samarasinghe13*

1Great Ormond Street Hospital, London, United Kingdom
2Institute of Child Health, London, United Kingdom
3Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, United Kingdom
4Newcastle University, Newcastle, United Kingdom
5NICR, Newcastle, GBR
6Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom
7John Radcliffe, Oxford, United Kingdom
8Royal Hospital for Children and Young People, Edinburgh, United Kingdom
9Birmingham Children's Hospital, Birmingham, GBR
10UCLH, London, GBR
11Bristol Children's Hospital, Bristol, United Kingdom
12Great Ormond Street Hospital, London, GBR
13Great Ormond Street Hospital, London,, United Kingdom


UKALL 2011 is a randomised study recruiting children and young adults (up to 25) with Acute Lymphoblastic Leukaemia (ALL) or Lymphoblastic Lymphoma (LBL). One of the aims of the trial was to reduce maintenance morbidity by randomising to Vincristine (VCR)/dexamethasone pulses or not. Results of this randomisation were presented at ASH 2022. In a sub-study, we also aimed to determine the natural history of vincristine induced neuropathy (VIN), including patients randomised to vincristine in maintenance or not and to determine pharmacogenomic risk factors for VIN.


Children and adolescents, aged 5-18yrs, were recruited from 5 centres in the UK. Patients were stratified by NCI risk, cytogenetics and end of induction MRD to receive Regimens A (NCI standard risk, MRD low risk), B (NCI high risk, MRD low risk) or C (Cytogenetic poor risk or MRD intermediate risk regardless of NCI risk). The maximum total number of vincristine doses was dependent on regimen and gender: females - Regimen A/B 33, Regimen C 42; males Regimen A/B 46, Regimen C 55. VIN was assessed at 7 time points (diagnosis, end of induction, delayed intensification, maintenance cycles 1,3 & 5 and end of treatment) using the Paediatric TNSr-Vincristine. The Paediatric TNSr-Vincristine assessed proximal extension of numbness, vibration, temperature sensation, muscle strength, tendon reflexes, constipation and hoarseness with each item scored from 0-4, with higher scores indicating more severe neuropathy (n=67). To assess how walking was affected, gait assessment was completed using the GAITRite® walkway-a mat embedded with several thousand electronic pressure sensors activated by mechanical pressure that captured key walking outcomes (velocity, cadence and step length) (n=46). The gait parameters were analysed and compared with age and gender matched controls enabling Z-scores comparison to normal controls. Nine candidate SNPs associated with VIN were genotyped (n=58) and were analysed against highest TNS score at any timepoint and TNS scores above and below the mean. 39 children were randomised to vincristine or not (20 vincristine vs. 19 no vincristine).

We fitted linear mixed-effects regression. Predictive factors included genetics; treatment time point; post induction regime (C vs A/B). For the randomised cohort the effect of pulsed vincristine was explored. All tests were two-sided, with significance determined as p<0.05. We adjusted the effects in the model to accommodate effect of age and gender on the total neuropathy score for paediatrics. Analyses were performed using R version 4.3.1.


Compared to diagnosis, the likelihood of VIN increased between end of induction and intensification, and then reduced over subsequent visits, but remained significantly abnormal at end of treatment (TNS incident rate ratio (IRR) 6.2 (end of induction/intensification vs diagnosis); 4.1 (end of treatment vs diagnosis); p<0.001) (Fig 1). Older children were more likely to have a higher TNS score (IRR 2.4 (p=0.003). Velocity, cadence and step length data were significantly affected compared to normal standards (p<0.001; Figure 2). Regimen C led to a reduction in step length Z-score of a third ((L) p=0.05; (R) p=0.03)). The likelihood of a higher VIN score in patients randomised to pulsed vincristine in maintenance compared to no vincristine was borderline significant (TNS score (IRR) 1.31 with a confidence interval of 1.00-1.71 (p=0.05)). When analysed by ABCB1 haplotype, TTT/TTT carrier status (loci rs1045642, rs1128503 and rs2032582) was significantly associated with lower TNS scores (p=0.04), whilst the CEP72 TT genotype was significantly associated with TNS scores below the mean (p=0.03) in contrast to previous literature and the ABCB1 rs2032582 G allele was associated with significantly higher mean TNS scores (p=0.04),


VIN increases with intensity of vincristine treatment and does not normalise at the end of treatment. VIN led to a slower gait and shorter steps whilst removing vincristine in maintenance was associated with reduced likelihood of VIN. VIN was not strongly influenced by any single genotype in this cohort. Conflicting pharmacogenomics results could be explained by differences in ethnicity, protocol design and relatively small numbers in this analysis. Gait analysis represents a novel functional method of assessing VIN enabling comparison to normal age matched peers.

Disclosures: Kirkwood: Kite-Gilead: Honoraria. Kearns: AstraZeneca: Consultancy. Samarasinghe: Jazz Pharmaceuticals: Honoraria; Pfizer: Honoraria.

*signifies non-member of ASH